# How an mRNA Vaccine Teaches Your Body to Fight Rabies > This patent describes a method for creating an immune response against the rabies virus by injecting a specific messenger RNA molecule that instructs cells to produce a key rabies protein. - **Patent:** US 12083190 - **Original title:** Rabies vaccine - **Owner:** Curevac SE - **Granted:** 2024 - **Status:** Active - **Times cited:** 0 - **Field:** biotech, pharmaceutical, telecommunications ## What it does This patent details a method to stimulate a protective immune response against the rabies virus. It involves administering a pharmaceutical composition containing a purified mRNA molecule (Claim 1). This mRNA molecule is engineered with specific parts: a 5′ Cap, an Open Reading Frame (ORF) that codes for the Rabies virus glycoprotein (RAV-G), and a Poly(A) sequence. The ORF is very similar (at least 95% identical) to a specific genetic sequence (SEQ ID NO: 24) for the RAV-G protein. The composition is delivered by injection, typically into a muscle or just under the skin (Claim 2, 3). For example, a person would receive an intramuscular shot containing this specially designed mRNA, and their cells would then temporarily produce the RAV-G protein, triggering an immune response without causing disease. ## What it does NOT cover - Does not cover rabies vaccines that use inactivated virus or live-attenuated virus, as it specifically claims a purified mRNA molecule. - Does not cover mRNA vaccines for rabies that do not encode the Rabies virus glycoprotein (RAV-G) or a sequence at least 95% identical to SEQ ID NO: 24. - Does not cover methods of administration other than injection, such as oral vaccines or nasal sprays. - Does not cover mRNA compositions that lack a 5' Cap or a Poly(A) sequence, which are essential elements of the claimed mRNA molecule. - Does not cover mRNA vaccines for rabies that are not formulated with a cationic or polycationic compound if administered intramuscularly (Claim 15). ## The clever bit The novelty lies in the specific design of the mRNA molecule to efficiently produce the rabies glycoprotein (RAV-G) in human cells, including elements like a specific 5' Cap, a Poly(A) sequence, and potentially an increased G/C content in the ORF for better protein production, all within a lipid formulation for effective delivery. ## Real-world examples 1. CureVac's investigational mRNA rabies vaccine candidates 2. Other mRNA vaccine platforms targeting viral glycoproteins 3. Future mRNA vaccines for infectious diseases ## Why it matters Rabies is a deadly viral disease, and effective vaccines are crucial for both prevention and post-exposure treatment. This patent contributes to the development of mRNA-based vaccines, a technology that gained significant attention and validation with COVID-19 vaccines. mRNA vaccines offer advantages like rapid development and manufacturing scalability compared to traditional vaccine approaches. CureVac SE, the assignee, is a key player in advancing mRNA technology for various diseases. ## Frequently asked questions ### What does How an mRNA Vaccine Teaches Your Body to Fight Rabies cover? This patent describes a method for creating an immune response against the rabies virus by injecting a specific messenger RNA molecule that instructs cells to produce a key rabies protein. ### Who owns patent US 12083190? Curevac SE owns this patent, granted in 2024. ### When does this patent expire? This patent is expected to expire on May 17, 2042, when the invention enters the public domain. ### What problem does this patent solve? Rabies is a deadly viral disease, and effective vaccines are crucial for both prevention and post-exposure treatment. This patent contributes to the development of mRNA-based vaccines, a technology that gained significant attention and validation with COVID-19 vaccines. mRNA vaccines offer advantages like rapid development and manufacturing scalability compared to traditional vaccine approaches. CureVac SE, the assignee, is a key player in advancing mRNA technology for various diseases. ### What does this patent NOT cover? Does not cover rabies vaccines that use inactivated virus or live-attenuated virus, as it specifically claims a purified mRNA molecule. **Full plain-English explainer:** https://patentbrief.org/patent/us/12083190/rabies-vaccine **Original patent:** https://patents.google.com/patent/US12083190 --- _Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._ ## Related patents Semantically similar inventions in the PatentBrief corpus: - [How Moderna's mRNA Vaccine Technology Targets Betacoronaviruses](https://patentbrief.org/patent/us/10702600/betacoronavirus-mrna-vaccine) — A patent describing a specific mRNA vaccine design that uses lipid nanoparticles to deliver genetic instructions for building parts of a betacoronavirus to trigger an immune response. - [How Modified RNA Tricks Cells Into Making Proteins Without Triggering Attacks](https://patentbrief.org/patent/us/8278036/rna-containing-modified-nucleosides-and-methods-of-use-thereof) — A breakthrough method for using modified RNA to deliver instructions to cells without causing the body to reject the treatment as a foreign invader. - [How an mRNA Vaccine Targets Prostate Cancer with Six Antigens](https://patentbrief.org/patent/us/20160166668/composition-and-vaccine-for-treating-prostate-cancer) — This patent describes an mRNA vaccine designed to treat prostate cancer by delivering genetic instructions for a specific combination of six prostate-related proteins, teaching the body to fight the cancer. - [Using mRNA to Teach the Body to Fight Prostate Cancer](https://patentbrief.org/patent/us/12048738/composition-for-treating-prostate-cancer-pca) — This patent describes an active composition, often a vaccine, that uses messenger RNA (mRNA) to instruct a mammal's cells to produce specific prostate cancer proteins, thereby training the immune system to attack prostate cancer cells. - [How an mRNA Vaccine for Lung Cancer Teaches the Immune System to Fight](https://patentbrief.org/patent/us/20160168227/composition-and-vaccine-for-treating-lung-cancer) — This patent describes a specific mRNA vaccine designed to treat lung cancer by instructing the body's cells to produce six distinct tumor proteins, thereby training the immune system to recognize and attack cancer cells.